Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?

@article{MorenoFierros2020DevelopmentOS,
  title={Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?},
  author={Leticia Moreno-Fierros and Ileana Garc{\'i}a-Silva and Sergio Rosales-Mendoza},
  journal={Expert Opinion on Biological Therapy},
  year={2020},
  volume={20},
  pages={831 - 836}
}
The COVID-19 pandemic caused by the SARS-CoV-2 virus is having an unprecedented impact on global health derived from its quick spread, which is attributed to its high stability under environmental ... 
SARS-CoV-2 vaccines, where do we stand?
Vaccination against the SARS-CoV-2, the virus responsible for the Covid-19 pandemic, represents a major infection control strategy in the absence of effective treatment of the disease to date.
Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
TLDR
The identification of immune correlates of protection will facilitate the development of effective vaccines and therapeutics strategies and contribute to lower risk of infection and amelioration of disease severity.
The challenges of COVID‐19 Delta variant: Prevention and vaccine development
TLDR
This work comprehensively described the evaluation and features of Delta variant, summarized the effects of mutations in spike on the infectivity, transmission ability, immune evasion, and provided a perspective on efficient approaches for preventing and overcoming COVID‐19.
Immunological considerations for COVID-19 vaccine strategies
TLDR
The immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies are discussed and their strengths and potential shortfalls are examined, and inferences about their chances of success are made.
Research, Development and Application of COVID-19 Vaccines: Progress, Challenges, and Prospects
The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the most formidable challenge to humanity in this
COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
  • Ramandeep Singh, A. Kang, +4 authors Z. Xing
  • Medicine
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2021
TLDR
A comprehensive overview to conceptually thread together the latest information on global epidemiology and mitigation strategies, clinical features, viral pathogenesis and immune responses, and the current state of vaccine development is provided.
Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms
TLDR
The considerable immunological aspects, potential antigen targets, appropriate adjuvants as well as key points in the various stages of COVID-19 vaccine development are introduced and the principal features of the preclinical and clinical studies of pioneering COVID -19 vaccine candidates were pointed out.
Repurposing NASVAC, a hepatitis B therapeutic vaccine, for pre- and postexposure prophylaxis of SARS-CoV-2 infection
TLDR
The pattern of cytokine responses and absence of infection or mild COVID-19 infection of the subjects involved in the study are preliminary evidence indicating that this product may prevent or suppress SARS -CoV -2 infection at the initial stages of SARS-CoV-2 acquisition and/or replication.
Mucosal and transdermal vaccine delivery strategies against COVID-19
TLDR
This short report discusses these unconventional formulations against COVID-19, in brief, to stress the importance of research in the field of drug delivery.
Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules
TLDR
The current opinion article conveys the thoughts and perspectives on the promising usage of plant-based biomolecules in circumventing SARS-CoV-2, and how these molecules can work synergistically with other potential drugs for treating Sars-Co V-2.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Evidence for Gastrointestinal Infection of SARS-CoV-2
No abstract available Keywords: ACE2; Gastrointestinal Infection; Oral-Fecal Transmission; SARS-CoV-2.
The SARS-CoV-2 Vaccine Pipeline: an Overview
TLDR
It is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration.
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
TLDR
Recent advances in the development of vaccines and therapeutics based on the S protein are highlighted, which plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV.
PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV
TLDR
It is demonstrated that the intraperitoneal and intranasal co-administration of inactivated SARS-CoV vaccine together with this improved Poly (I:C) derivative induced strong anti-SARS- CoV mucosal and systemic humoral immune responses with neutralizing activity against pseudotyped virus.
A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus
TLDR
It is demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA–NC by intramuscular route.
An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
TLDR
It is shown that a modified vaccinia virus Ankara (MVA) vaccine expressing the MERS-CoV spike protein confers mucosal immunity in dromedary camels, and that induction of MVA-specific antibodies that cross-neutralize camelpox virus would also provide protection against camelpox.
Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses
TLDR
It is shown that induction of airway memory CD4+ T cells specific for a conserved epitope shared by SARS- coV and MERS-CoV is a potential strategy for developing pan-coronavirus vaccines.
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
TLDR
The structure and function of key proteins of emerging human CoVs are described, the current vaccine types to be developed against SARS- coV and MERS-CoV are overviewed, and recent advances in subunit vaccines against these two pathogenic human CoV are summarized.
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus
TLDR
These analyses provide insights into the receptor usage, cell entry, host cell infectivity and animal origin of 2019-nCoV and may help epidemic surveillance and preventive measures against 2019- nCoV.
A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice
TLDR
The results showed that GEL01-adjuvanted RLP3-GEM increased the systemic humoral, cellular and local mucosal immune responses in the mouse model, especially in the intestinal tract.
...
1
2
3
4
5
...